SCHEMBL4803537

SCHEMBL4803537

CSc1nc(SC)c(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
HSP90AB1 P08238 1/20 0.43
CNR1 P21554 5/20 0.40
CNR2 P34972 4/20 0.40
CRHR1 P34998 1/20 0.40
DPP4 P27487 1/20 0.40
HSD11B1 P28845 1/20 0.40
MEN1 O00255 2/20 0.39
LMNA P02545 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4810291 0.85 KDM4E (0.42) KDM4EHSP90AB1CNR1CNR2DPP4
SCHEMBL4809965 0.83 CNR1 (0.46) KDM4ECNR1CNR2CRHR1DPP4
SCHEMBL4802465 0.78 CNR1 (0.39) KDM4ECNR1CNR2CRHR1DPP4
SCHEMBL4804885 0.77 CNR1 (0.49) CNR1CNR2
SCHEMBL4811008 0.76 CNR1 (0.45) KDM4EHSP90AB1CNR1CNR2CRHR1
SCHEMBL4807124 0.74 KDM4E (0.44) KDM4EHSP90AB1CNR1CNR2HSD11B1
SCHEMBL4804829 0.74 CNR1 (0.60) CNR1CNR2
SCHEMBL4809956 0.74 TDP1 (0.39) KDM4EHSP90AB1CNR1CNR2CRHR1
SCHEMBL4094400 0.71 HSP90AB1 (0.55) KDM4EHSP90AB1CRHR1DPP4NPC1
SCHEMBL6049455 0.71 HSP90AA1 (0.53) KDM4EHSP90AB1CRHR1DPP4HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7405221-B2 Substituted pyrimidines MERCK & CO., INC. (US) 2008-07-29 US disclosed
US-7405221-B2 Substituted pyrimidines MERCK & CO., INC. (US) 2008-07-29 US disclosed
US-7405221-B2 Substituted pyrimidines MERCK & CO., INC. (US) 2008-07-29 US disclosed
US-20050245554-A1 Substituted pyrimidines MERCK SHARP & DOHME CORP. 2005-11-03 US disclosed
EP-1546115-A2 SUBSTITUTED PYRIMIDINES Merck & Co., Inc. (US) 2005-06-29 EP disclosed
WO-2004029204-A2 SUBSTITUTED PYRIMIDINES MERCK & CO., INC. (US) 2004-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245554-A1 Substituted pyrimidines CNR1, CNR2, GPR119 KDM4E 3554/4885HSP90AB1 3714/4885CNR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.